BUZZ-美国食品和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨

路透中文

Jan 29

BUZZ-<a href="https://laohu8.com/S/USFD">美国食品</a>和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨

1月29日 - ** 药物开发商Summit Therapeutics SMMT.O股价盘前上涨3.71%至16.22美元

** 该公司称美国食品和药物管理局已接受其治疗肺癌的实验性药物的上市申请

** 报告称，9月份对其晚期试验进行的长期随访中，病人分组的结果参差不齐 (link)。

** 该疗法是一种抗体，旨在阻断一种名为 PD-1 的蛋白质，这种蛋白质可帮助人体免疫系统抵御癌症；Keytruda 也针对相同的蛋白质。

** 卫生监管机构已将新的《处方药用户费法》(PDUFA) 目标行动日期定为 2026 年 11 月 14 日 - SMMT

** 2025 年股价下跌 ~2%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607087785"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607087785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607087785?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-29 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607087785","market":"us","top_or_hot":-1,"title":"BUZZ-美国食品和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/USFD\">美国食品</a>和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨</title></head><body><p>\n<span>1月29日</span><span> - </span>** 药物开发商<a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SMMT.O</span>股价盘前上涨3.71%至16.22美元</p><p>** 该公司称美国食品和药物管理局已接受其治疗肺癌的实验性药物的上市申请 </p><p>** 报告称，9月份对其晚期试验进行的长期随访中，病人分组的结果参差不齐 (<span>link</span>)。</p><p>** 该疗法是一种抗体，旨在阻断一种名为 PD-1 的蛋白质，这种蛋白质可帮助人体免疫系统抵御癌症；Keytruda 也针对相同的蛋白质。 </p><p>** 卫生监管机构已将新的《处方药用户费法》(PDUFA) 目标行动日期定为 2026 年 11 月 14 日 - SMMT</p><p>** 2025 年股价下跌 ~2%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-美国食品和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-美国食品和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-29 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/USFD\">美国食品</a>和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨</title></head><body><p>\n<span>1月29日</span><span> - </span>** 药物开发商<a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SMMT.O</span>股价盘前上涨3.71%至16.22美元</p><p>** 该公司称美国食品和药物管理局已接受其治疗肺癌的实验性药物的上市申请 </p><p>** 报告称，9月份对其晚期试验进行的长期随访中，病人分组的结果参差不齐 (<span>link</span>)。</p><p>** 该疗法是一种抗体，旨在阻断一种名为 PD-1 的蛋白质，这种蛋白质可帮助人体免疫系统抵御癌症；Keytruda 也针对相同的蛋白质。 </p><p>** 卫生监管机构已将新的《处方药用户费法》(PDUFA) 目标行动日期定为 2026 年 11 月 14 日 - SMMT</p><p>** 2025 年股价下跌 ~2%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nL4S3YU1U5:1","article_id":"2607087785","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607087785","pubTimestamp":1769692050,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"1月29日 - ** 药物开发商Summit Therapeutics SMMT.O股价盘前上涨3.71%至16.22美元** 该公司称美国食品和药物管理局已接受其治疗肺癌的实验性药物的上市申请 ** 报告称，9月份对其晚期试验进行的长期随访中，病人分组的结果参差不齐 。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","SMMT":"Summit Therapeutics PLC"},"translate_title":"BUZZ-Gaofeng Pharmaceuticals rises after FDA accepts marketing application for lung cancer drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":0.9},"content_text":"BUZZ-美国食品和药物管理局接受肺癌药物上市申请后，高峰药业股价上涨\n1月29日 - ** 药物开发商Summit Therapeutics SMMT.O股价盘前上涨3.71%至16.22美元** 该公司称美国食品和药物管理局已接受其治疗肺癌的实验性药物的上市申请 ** 报告称，9月份对其晚期试验进行的长期随访中，病人分组的结果参差不齐 (link)。** 该疗法是一种抗体，旨在阻断一种名为 PD-1 的蛋白质，这种蛋白质可帮助人体免疫系统抵御癌症；Keytruda 也针对相同的蛋白质。 ** 卫生监管机构已将新的《处方药用户费法》(PDUFA) 目标行动日期定为 2026 年 11 月 14 日 - SMMT** 2025 年股价下跌 ~2%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}